{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_notes_note in Note (approximate match)
Status:
Investigational
Source:
JAN:L-TYROSINE ETHYLESTER MONOHYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tyrosine ethyl ester hydrochloride is used as a medical and organic intermediate and as an important amino protective agent. It is also used to introduce t-Boc protect gene. Tyrosine ethyl ester hydrochloride is used as a supplement (tyrosine).
Status:
Investigational
Source:
NCT01004315: Phase 3 Interventional Completed Overactive Bladder
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.
Status:
Investigational
Source:
NCT01004315: Phase 3 Interventional Completed Overactive Bladder
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.
![Structure of 2-[(1S,2S)-1-Ethyl-2-(phenylmethoxy)propyl]hydrazinecarboxaldehyde oxalic acid](/img/503e1abc-2adc-4625-b1a6-db232d0a1469.svg?size=200&context=sxbbomrrmy)
![Structure of Ethyl (2R,5S)-5-[(phenylmethoxy)amino]-2-piperidinecarboxylate oxalate](/img/855f24f0-5694-40b7-91e8-f1cccc9079ed.svg?size=200&context=sxbbomrrmy)
![Structure of 4-[[[(3S,4S)-3-[[[(1R)-1-(1-Naphthyl)ethyl]amino]methyl]-4-phenylpyrrolidin-1-yl]carbonyl]oxy]benzoic acid hydrochloride](/img/66faf93f-faec-47f5-8999-eaf237ef4ab4.svg?size=200&context=sxbbomrrmy)
![Structure of (5R,6S)-6-[(1R)-1-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]ethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt](/img/57e385b1-f393-4c13-8afc-e5aec0a7288e.svg?size=200&context=sxbbomrrmy)
![Structure of 4H-1,2,4-Triazolium, 1-[(2R,3R)-3-[4-(4-cyanophenyl)-2-thiazolyl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4-[1-[[[[3-[[[2-[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]oxy]methyl]-2-pyridinyl]methylamino]carbonyl]oxy]ethyl]-, iodide (1:1)](/img/2b4c7574-f3b0-456f-ad07-b57caf7a5f03.svg?size=200&context=sxbbomrrmy)
![Structure of [2-(4-Methoxyphenyl)ethyl]dimethylamine hydrochloride](/img/3b3528af-9da5-4b04-b17d-586d03c3e97b.svg?size=200&context=sxbbomrrmy)